RESUMO
AIM: To evaluate the efficacy and safety of riamilovir in the treatment of COVID-19 in adults. MATERIALS AND METHODS: The study included 180 patients with a laboratory-confirmed diagnosis of COVID-19 which fully meet the criteria for inclusion, non-inclusion and exclusion, signed a voluntary informed consent to participate in a clinical trial. RESULTS: The efficacy, good tolerability and safety of the drug riamilovir in the treatment of COVID-19 have been established. CONCLUSION: As a result of a multicenter randomized double-blind clinical trial, the effectiveness of the drug riamilovir for therapeutic use in patients with COVID-19 according to the 1250 mg/day scheme (250 mg capsules 5 times per day) for 10 days was established. The drug riamilovir in a daily dose of 1250 mg for 10 days does not differ in safety from placebo.
Assuntos
Tratamento Farmacológico da COVID-19 , Humanos , Método Duplo-Cego , Masculino , Feminino , Pessoa de Meia-Idade , Adulto , Resultado do Tratamento , Antivirais/administração & dosagem , Antivirais/efeitos adversos , Antivirais/uso terapêutico , COVID-19 , SARS-CoV-2RESUMO
This paper presents a review of the literature on the mechanisms of development the syndrome of endogenous intoxication. Given the different definitions the syndrome of endogenous intoxication, the phase of pathogenesis, the basic mechanisms of its development. The characteristic of endotoxic substances, their effects on the body as a whole and on the organs of detoxification, in particular. It is shown that the main role of the liver to detoxify the body and its functions in violation of the incidence of virus hepatitis. The methods of diagnosis of the syndrome of endogenous intoxication.
